Novalgin (Metamizole Sodium Monohydrate)

Metamizole sodium works mainly by inhibiting cyclooxygenase enzymes, which reduces the synthesis of prostaglandins involved in pain perception and temperature regulation. Additionally, it has spasmolytic properties that relax smooth muscle, helping to relieve visceral colic and related discomfort.

The appropriate dose of Novalgin is determined by the prescribing clinician based on the patient’s condition, age, weight, and clinical response. Dosage regimens may differ for intramuscular versus intravenous administration, and the prescriber will tailor the regimen to each individual case.

The safety of metamizole sodium in pregnancy and lactation has not been definitively established. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Novalgin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Novalgin offers a non‑opioid alternative to NSAIDs and opioid analgesics. Compared with NSAIDs, it has a lower risk of gastrointestinal irritation but carries a rare risk of agranulocytosis. Unlike opioids, it does not cause respiratory depression, making it useful when opioid‑related side effects are a concern.

Novalgin injectable solution should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Prior to administration, allow the product to reach room temperature if required, and inspect for particulate matter or discoloration before use.

Novalgin is administered by a healthcare professional either intramuscularly or intravenously. The solution is typically drawn into a sterile syringe, and the injection site is prepared according to aseptic technique. Dosage and rate of infusion are determined by the prescriber based on the clinical situation.

The most serious adverse reactions associated with Novalgin are agranulocytosis, a potentially fatal drop in white blood cells, and severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should be monitored for signs of infection, fever, or skin changes, and treatment should be stopped immediately if these occur.

Novalgin is contraindicated in individuals with a known hypersensitivity to metamizole or any pyrazolone derivatives, in patients with a history of agranulocytosis, and in those receiving other myelosuppressive agents without close monitoring. Caution is also advised for patients with severe renal or hepatic impairment.